InsidersTradesSigma
Follow the 健民集团 stock price and the full management transaction log of the company, a listed equity based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 健民集团 has logged 7 public disclosures. Market capitalisation: €4.3bn. The latest transaction was disclosed on 4 April 2023 (Sale). Among the most active insiders: 黄芳晶父亲. Every trade is free.
7
Insider Decl.
n/a
Thresholds
€3,374
1 ops.
Buy Volume
€34,966
6 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,395 of 29,057 companies
72.3
score / 100
Value69
Quality76
FCF yld4.1%
Earn yld8.4%
EV/EBITDA9.8x
ROE13%
Gross mgn58%
Net mgn11%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 April 2023
Declarations7 total
7 of 7 declarations
About 健民集团
健民集团 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the research, development, and production of medicines and pharmaceutical products.